The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis

It is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients. 80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.

NCT Number	NCT07168772
Lead Sponsor	Hospital Universitari Vall d'Hebron Research Institute
Conditions	Multiple Sclerosis
Enrollment	80 participants
Start Date	2025-07-10
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07